SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS
Delisted
SYRS was delisted on the 19th of March, 2025.
64 hedge funds and large institutions have $40.7M invested in Syros Pharmaceuticals, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding in top 10
Funds holding in top 10: →
61% less capital invested
Capital invested by funds: $105M → $40.7M (-$64.5M)
90% less call options, than puts
Call options by funds: $281K | Put options by funds: $2.73M
Holders
64
Holding in Top 10
1
Calls
$281K
Puts
$2.73M
Top Buyers
| 1 | +$376K | |
| 2 | +$300K | |
| 3 | +$175K | |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$107K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$106K |
Top Sellers
| 1 | -$12.9M | |
| 2 | -$2.21M | |
| 3 | -$1.35M | |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$1.31M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$701K |